Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 34 entries
Sorted by: Best Match Show Resources per page
Dosimetry and toxicity outcomes in postoperative high-dose-rate intracavitary brachytherapy for endometrial carcinoma.

Journal of contemporary brachytherapy

Donnelly ED, Rakhra S, Helenowski I, Gopalkrishnan M, Lurain J, Schink J, Singh D, Strauss J, Small W.
PMID: 23346142
J Contemp Brachytherapy. 2012 Sep;4(3):135-40. doi: 10.5114/jcb.2012.30679. Epub 2012 Sep 29.

PURPOSE: The optimal dosimetric parameters and planning techniques for high-dose-rate vaginal brachytherapy (HDR-VB) are unclear. Our aim was to evaluate the utility of bladder and rectal dosimetry for patients receiving HDR-VB for postoperative treatment of endometrial carcinoma.MATERIAL AND METHODS:...

Cite
Donnelly ED, Rakhra S, Helenowski I, et al. Dosimetry and toxicity outcomes in postoperative high-dose-rate intracavitary brachytherapy for endometrial carcinoma. J Contemp Brachytherapy. 2012;4(3):135-40doi: 10.5114/jcb.2012.30679.
Donnelly, E. D., Rakhra, S., Helenowski, I., Gopalkrishnan, M., Lurain, J., Schink, J., Singh, D., Strauss, J., & Small, W. (2012). Dosimetry and toxicity outcomes in postoperative high-dose-rate intracavitary brachytherapy for endometrial carcinoma. Journal of contemporary brachytherapy, 4(3), 135-40. https://doi.org/10.5114/jcb.2012.30679
Donnelly, Eric D, et al. "Dosimetry and toxicity outcomes in postoperative high-dose-rate intracavitary brachytherapy for endometrial carcinoma." Journal of contemporary brachytherapy vol. 4,3 (2012): 135-40. doi: https://doi.org/10.5114/jcb.2012.30679
Donnelly ED, Rakhra S, Helenowski I, Gopalkrishnan M, Lurain J, Schink J, Singh D, Strauss J, Small W. Dosimetry and toxicity outcomes in postoperative high-dose-rate intracavitary brachytherapy for endometrial carcinoma. J Contemp Brachytherapy. 2012 Sep;4(3):135-40. doi: 10.5114/jcb.2012.30679. Epub 2012 Sep 29. PMID: 23346142; PMCID: PMC3551376.
Copy Download .nbib Format: NLM
Corrections to "A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma".

Annals of oncology : official journal of the European Society for Medical Oncology

Evens AM, Carson KR, Kolesar J, Nabhan C, Helenowski I, Islam N, Jovanovic B, Barr PM, Caimi PF, Gregory SA, Gordon LI.
PMID: 32018560
Ann Oncol. 2014 Jul;25(7):1449. doi: 10.1093/annonc/mdu179. Epub 2019 Dec 04.

No abstract available.

Cite
Evens AM, Carson KR, Kolesar J, et al. Corrections to "A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma". Ann Oncol. 2019;25(7):1449doi: 10.1093/annonc/mdu179.
Evens, A. M., Carson, K. R., Kolesar, J., Nabhan, C., Helenowski, I., Islam, N., Jovanovic, B., Barr, P. M., Caimi, P. F., Gregory, S. A., & Gordon, L. I. (2014). Corrections to "A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma". Annals of oncology : official journal of the European Society for Medical Oncology, 25(7), 1449. https://doi.org/10.1093/annonc/mdu179
Evens, A M, et al. "Corrections to "A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma"." Annals of oncology : official journal of the European Society for Medical Oncology vol. 25,7 (2014): 1449. doi: https://doi.org/10.1093/annonc/mdu179
Evens AM, Carson KR, Kolesar J, Nabhan C, Helenowski I, Islam N, Jovanovic B, Barr PM, Caimi PF, Gregory SA, Gordon LI. Corrections to "A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma". Ann Oncol. 2014 Jul;25(7):1449. doi: 10.1093/annonc/mdu179. Epub 2019 Dec 04. PMID: 32018560; PMCID: PMC4351366.
Copy Download .nbib Format: NLM
Selective progesterone receptor blockade prevents BRCA1-associated mouse mammary tumors through modulation of epithelial and stromal genes.

Cancer letters

Lee O, Bosland MC, Wang M, Shidfar A, Hosseini O, Xuei X, Patel P, Schipma MJ, Helenowski I, Kim JJ, Clare SE, Khan SA.
PMID: 34329741
Cancer Lett. 2021 Nov 01;520:255-266. doi: 10.1016/j.canlet.2021.07.034. Epub 2021 Jul 27.

Pharmacological approaches to breast cancer risk-reduction for BRCA1 mutation carriers would provide an alternative to mastectomy. BRCA1-deficiency dysregulates progesterone signaling, promoting tumorigenesis. Selective progesterone receptor (PR) modulators (SPRMs) are therefore candidate prevention agents. However, their efficacy varies in different...

Cite
Lee O, Bosland MC, Wang M, et al. Selective progesterone receptor blockade prevents BRCA1-associated mouse mammary tumors through modulation of epithelial and stromal genes. Cancer Lett. 2021;520:255-266doi: 10.1016/j.canlet.2021.07.034.
Lee, O., Bosland, M. C., Wang, M., Shidfar, A., Hosseini, O., Xuei, X., Patel, P., Schipma, M. J., Helenowski, I., Kim, J. J., Clare, S. E., & Khan, S. A. (2021). Selective progesterone receptor blockade prevents BRCA1-associated mouse mammary tumors through modulation of epithelial and stromal genes. Cancer letters, 520255-266. https://doi.org/10.1016/j.canlet.2021.07.034
Lee, Oukseub, et al. "Selective progesterone receptor blockade prevents BRCA1-associated mouse mammary tumors through modulation of epithelial and stromal genes." Cancer letters vol. 520 (2021): 255-266. doi: https://doi.org/10.1016/j.canlet.2021.07.034
Lee O, Bosland MC, Wang M, Shidfar A, Hosseini O, Xuei X, Patel P, Schipma MJ, Helenowski I, Kim JJ, Clare SE, Khan SA. Selective progesterone receptor blockade prevents BRCA1-associated mouse mammary tumors through modulation of epithelial and stromal genes. Cancer Lett. 2021 Nov 01;520:255-266. doi: 10.1016/j.canlet.2021.07.034. Epub 2021 Jul 27. PMID: 34329741.
Copy Download .nbib Format: NLM
The association of phosphodiesterase-5 inhibitors with the biochemical recurrence-free and overall survival of patients with prostate cancer following radical prostatectomy.

Urologic oncology

Danley KT, Tan A, Catalona WJ, Leikin R, Helenowski I, Jovanovic B, Gurley M, Kuzel TM.
PMID: 34284930
Urol Oncol. 2021 Jul 18; doi: 10.1016/j.urolonc.2021.05.031. Epub 2021 Jul 18.

PURPOSE: To determine whether phosphodiesterase-5 inhibitor documentation is associated with biochemical relapse-free and overall survival of patients with prostate cancer treated with radical prostatectomy.MATERIALS AND METHODS: We undertook a retrospective cohort analysis of 3,100 patients with prostate cancer treated...

Cite
Danley KT, Tan A, Catalona WJ, et al. The association of phosphodiesterase-5 inhibitors with the biochemical recurrence-free and overall survival of patients with prostate cancer following radical prostatectomy. Urol Oncol. 2021;doi: 10.1016/j.urolonc.2021.05.031.
Danley, K. T., Tan, A., Catalona, W. J., Leikin, R., Helenowski, I., Jovanovic, B., Gurley, M., & Kuzel, T. M. (2021). The association of phosphodiesterase-5 inhibitors with the biochemical recurrence-free and overall survival of patients with prostate cancer following radical prostatectomy. Urologic oncology, . https://doi.org/10.1016/j.urolonc.2021.05.031
Danley, Kelsey T, et al. "The association of phosphodiesterase-5 inhibitors with the biochemical recurrence-free and overall survival of patients with prostate cancer following radical prostatectomy." Urologic oncology vol. (2021). doi: https://doi.org/10.1016/j.urolonc.2021.05.031
Danley KT, Tan A, Catalona WJ, Leikin R, Helenowski I, Jovanovic B, Gurley M, Kuzel TM. The association of phosphodiesterase-5 inhibitors with the biochemical recurrence-free and overall survival of patients with prostate cancer following radical prostatectomy. Urol Oncol. 2021 Jul 18; doi: 10.1016/j.urolonc.2021.05.031. Epub 2021 Jul 18. PMID: 34284930.
Copy Download .nbib Format: NLM
Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment.

HGG advances

Jiang Y, Meyers TJ, Emeka AA, Cooley LF, Cooper PR, Lancki N, Helenowski I, Kachuri L, Lin DW, Stanford JL, Newcomb LF, Kolb S, Finelli A, Fleshner NE, Komisarenko M, Eastham JA, Ehdaie B, Benfante N, Logothetis CJ, Gregg JR, Perez CA, Garza S, Kim J, Marks LS, Delfin M, Barsa D, Vesprini D, Klotz LH, Loblaw A, Mamedov A, Goldenberg SL, Higano CS, Spillane M, Wu E, Carter HB, Pavlovich CP, Mamawala M, Landis T, Carroll PR, Chan JM, Cooperberg MR, Cowan JE, Morgan TM, Siddiqui J, Martin R, Klein EA, Brittain K, Gotwald P, Barocas DA, Dallmer JR, Gordetsky JB, Steele P, Kundu SD, Stockdale J, Roobol MJ, Venderbos LDF, Sanda MG, Arnold R, Patil D, Evans CP, Dall'Era MA, Vij A, Costello AJ, Chow K, Corcoran NM, Rais-Bahrami S, Phares C, Scherr DS, Flynn T, Karnes RJ, Koch M, Dhondt CR, Nelson JB, McBride D, Cookson MS, Stratton KL, Farriester S, Hemken E, Stadler WM, Pera T, Banionyte D, Bianco FJ, Lopez IH, Loeb S, Taneja SS, Byrne N, Amling CL, Martinez A, Boileau L, Gaylis FD, Petkewicz J, Kirwen N, Helfand BT, Xu J, Scholtens DM, Catalona WJ, Witte JS.
PMID: 34993496
HGG Adv. 2022 Jan 13;3(1). doi: 10.1016/j.xhgg.2021.100070. Epub 2021 Nov 19.

Men diagnosed with low-risk prostate cancer (PC) are increasingly electing active surveillance (AS) as their initial management strategy. While this may reduce the side effects of treatment for prostate cancer, many men on AS eventually convert to active treatment....

Cite
Jiang Y, Meyers TJ, Emeka AA, et al. Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment. HGG Adv. 2021;3(1)doi: 10.1016/j.xhgg.2021.100070.
Jiang, Y., Meyers, T. J., Emeka, A. A., Cooley, L. F., Cooper, P. R., Lancki, N., Helenowski, I., Kachuri, L., Lin, D. W., Stanford, J. L., Newcomb, L. F., Kolb, S., Finelli, A., Fleshner, N. E., Komisarenko, M., Eastham, J. A., Ehdaie, B., Benfante, N., Logothetis, C. J., Gregg, J. R., Perez, C. A., Garza, S., Kim, J., Marks, L. S., Delfin, M., Barsa, D., Vesprini, D., Klotz, L. H., Loblaw, A., Mamedov, A., Goldenberg, S. L., Higano, C. S., Spillane, M., Wu, E., Carter, H. B., Pavlovich, C. P., Mamawala, M., Landis, T., Carroll, P. R., Chan, J. M., Cooperberg, M. R., Cowan, J. E., Morgan, T. M., Siddiqui, J., Martin, R., Klein, E. A., Brittain, K., Gotwald, P., Barocas, D. A., Dallmer, J. R., Gordetsky, J. B., Steele, P., Kundu, S. D., Stockdale, J., Roobol, M. J., Venderbos, L. D. F., Sanda, M. G., Arnold, R., Patil, D., Evans, C. P., Dall'Era, M. A., Vij, A., Costello, A. J., Chow, K., Corcoran, N. M., Rais-Bahrami, S., Phares, C., Scherr, D. S., Flynn, T., Karnes, R. J., Koch, M., Dhondt, C. R., Nelson, J. B., McBride, D., Cookson, M. S., Stratton, K. L., Farriester, S., Hemken, E., Stadler, W. M., Pera, T., Banionyte, D., Bianco, F. J., Lopez, I. H., Loeb, S., Taneja, S. S., Byrne, N., Amling, C. L., Martinez, A., Boileau, L., Gaylis, F. D., Petkewicz, J., Kirwen, N., Helfand, B. T., Xu, J., Scholtens, D. M., Catalona, W. J., & Witte, J. S. (2022). Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment. HGG advances, 3(1), . https://doi.org/10.1016/j.xhgg.2021.100070
Jiang, Yu, et al. "Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment." HGG advances vol. 3,1 (2022). doi: https://doi.org/10.1016/j.xhgg.2021.100070
Jiang Y, Meyers TJ, Emeka AA, Cooley LF, Cooper PR, Lancki N, Helenowski I, Kachuri L, Lin DW, Stanford JL, Newcomb LF, Kolb S, Finelli A, Fleshner NE, Komisarenko M, Eastham JA, Ehdaie B, Benfante N, Logothetis CJ, Gregg JR, Perez CA, Garza S, Kim J, Marks LS, Delfin M, Barsa D, Vesprini D, Klotz LH, Loblaw A, Mamedov A, Goldenberg SL, Higano CS, Spillane M, Wu E, Carter HB, Pavlovich CP, Mamawala M, Landis T, Carroll PR, Chan JM, Cooperberg MR, Cowan JE, Morgan TM, Siddiqui J, Martin R, Klein EA, Brittain K, Gotwald P, Barocas DA, Dallmer JR, Gordetsky JB, Steele P, Kundu SD, Stockdale J, Roobol MJ, Venderbos LDF, Sanda MG, Arnold R, Patil D, Evans CP, Dall'Era MA, Vij A, Costello AJ, Chow K, Corcoran NM, Rais-Bahrami S, Phares C, Scherr DS, Flynn T, Karnes RJ, Koch M, Dhondt CR, Nelson JB, McBride D, Cookson MS, Stratton KL, Farriester S, Hemken E, Stadler WM, Pera T, Banionyte D, Bianco FJ, Lopez IH, Loeb S, Taneja SS, Byrne N, Amling CL, Martinez A, Boileau L, Gaylis FD, Petkewicz J, Kirwen N, Helfand BT, Xu J, Scholtens DM, Catalona WJ, Witte JS. Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment. HGG Adv. 2022 Jan 13;3(1). doi: 10.1016/j.xhgg.2021.100070. Epub 2021 Nov 19. PMID: 34993496; PMCID: PMC8725988.
Copy Download .nbib Format: NLM
Direct oral anticoagulants decrease treatment failure for acute lower extremity deep venous thrombosis.

Vascular

Hekman KE, Chao CL, Morgan CE, Helenowski IB, Eskandari MK.
PMID: 34569367
Vascular. 2021 Sep 26;17085381211042231. doi: 10.1177/17085381211042231. Epub 2021 Sep 26.

OBJECTIVE: Optimal medical therapy for acute lower extremity deep venous thrombosis (DVT) remains an enigma. While clinical trials demonstrate non-inferiority with an oral anti-Xa inhibitor, or direct oral anticoagulant (DOAC), versus combined low-molecular weight heparin (LMWH) and oral vitamin...

Cite
Hekman KE, Chao CL, Morgan CE, et al. Direct oral anticoagulants decrease treatment failure for acute lower extremity deep venous thrombosis. Vascular. 2021;17085381211042231doi: 10.1177/17085381211042231.
Hekman, K. E., Chao, C. L., Morgan, C. E., Helenowski, I. B., & Eskandari, M. K. (2021). Direct oral anticoagulants decrease treatment failure for acute lower extremity deep venous thrombosis. Vascular, 17085381211042231. https://doi.org/10.1177/17085381211042231
Hekman, Katherine E, et al. "Direct oral anticoagulants decrease treatment failure for acute lower extremity deep venous thrombosis." Vascular vol. (2021): 17085381211042231. doi: https://doi.org/10.1177/17085381211042231
Hekman KE, Chao CL, Morgan CE, Helenowski IB, Eskandari MK. Direct oral anticoagulants decrease treatment failure for acute lower extremity deep venous thrombosis. Vascular. 2021 Sep 26;17085381211042231. doi: 10.1177/17085381211042231. Epub 2021 Sep 26. PMID: 34569367.
Copy Download .nbib Format: NLM
Implications of Tumor Characteristics and Treatment Modality on Local Recurrence and Functional Outcomes in Children with Chest Wall Sarcoma: A Pediatric Surgical Oncology Research Collaborative Study.

Annals of surgery

Harris CJ, Helenowski I, Murphy AJ, Mansfield SA, LaQuaglia MP, Heaton TE, Cavalli M, Murphy JT, Newman E, Overmen RE, Kartal TT, Cooke-Barber J, Donaher A, Malek MM, Kalsi R, Kim ES, Zobel MJ, Goodhue CJ, Naik-Mathuria BJ, Jefferson IN, Roach JP, Mata C, Piché N, Joharifard S, Sultan S, Short SS, Meyers RL, Bleicher J, Le HD, Janek K, Bütter A, Davidson J, Aldrink JH, Richards HW, Tracy ET, Commander SJ, Fialkowski EA, Troutt M, Dasgupta R, Lautz TB.
PMID: 33156070
Ann Surg. 2020 Nov 04; doi: 10.1097/SLA.0000000000004579. Epub 2020 Nov 04.

OBJECTIVE: To determine the impact of tumor characteristics and treatment approach on (1) local recurrence, (2) scoliosis development and (3) patient-reported quality of life in children with sarcoma of the chest wall.SUMMARY BACKGROUND DATA: Children with chest wall sarcoma...

Cite
Harris CJ, Helenowski I, Murphy AJ, et al. Implications of Tumor Characteristics and Treatment Modality on Local Recurrence and Functional Outcomes in Children with Chest Wall Sarcoma: A Pediatric Surgical Oncology Research Collaborative Study. Ann Surg. 2020;doi: 10.1097/SLA.0000000000004579.
Harris, C. J., Helenowski, I., Murphy, A. J., Mansfield, S. A., LaQuaglia, M. P., Heaton, T. E., Cavalli, M., Murphy, J. T., Newman, E., Overmen, R. E., Kartal, T. T., Cooke-Barber, J., Donaher, A., Malek, M. M., Kalsi, R., Kim, E. S., Zobel, M. J., Goodhue, C. J., Naik-Mathuria, B. J., Jefferson, I. N., Roach, J. P., Mata, C., Piché, N., Joharifard, S., Sultan, S., Short, S. S., Meyers, R. L., Bleicher, J., Le, H. D., Janek, K., Bütter, A., Davidson, J., Aldrink, J. H., Richards, H. W., Tracy, E. T., Commander, S. J., Fialkowski, E. A., Troutt, M., Dasgupta, R., & Lautz, T. B. (2020). Implications of Tumor Characteristics and Treatment Modality on Local Recurrence and Functional Outcomes in Children with Chest Wall Sarcoma: A Pediatric Surgical Oncology Research Collaborative Study. Annals of surgery, . https://doi.org/10.1097/SLA.0000000000004579
Harris, Courtney J, et al. "Implications of Tumor Characteristics and Treatment Modality on Local Recurrence and Functional Outcomes in Children with Chest Wall Sarcoma: A Pediatric Surgical Oncology Research Collaborative Study." Annals of surgery vol. (2020). doi: https://doi.org/10.1097/SLA.0000000000004579
Harris CJ, Helenowski I, Murphy AJ, Mansfield SA, LaQuaglia MP, Heaton TE, Cavalli M, Murphy JT, Newman E, Overmen RE, Kartal TT, Cooke-Barber J, Donaher A, Malek MM, Kalsi R, Kim ES, Zobel MJ, Goodhue CJ, Naik-Mathuria BJ, Jefferson IN, Roach JP, Mata C, Piché N, Joharifard S, Sultan S, Short SS, Meyers RL, Bleicher J, Le HD, Janek K, Bütter A, Davidson J, Aldrink JH, Richards HW, Tracy ET, Commander SJ, Fialkowski EA, Troutt M, Dasgupta R, Lautz TB. Implications of Tumor Characteristics and Treatment Modality on Local Recurrence and Functional Outcomes in Children with Chest Wall Sarcoma: A Pediatric Surgical Oncology Research Collaborative Study. Ann Surg. 2020 Nov 04; doi: 10.1097/SLA.0000000000004579. Epub 2020 Nov 04. PMID: 33156070; PMCID: PMC8093319.
Copy Download .nbib Format: NLM
TRUE-Bolivia (Trauma Responders Unifying to Empower Communities Bolivia) in Santa Cruz, Bolivia.

The Journal of surgical research

Jackson ME, Ludi EK, Reitz ACW, Moraes Dos Santos G, Helenowski IB, Quiroga LL, Foianini JE, Swaroop M.
PMID: 34999516
J Surg Res. 2022 Jan 06;273:1-8. doi: 10.1016/j.jss.2021.12.006. Epub 2022 Jan 06.

BACKGROUND: The aim of this study is to assess the efficacy of the TRUE-Bolivia (Trauma Responders Unifying to Empower Communities Bolivia) trauma first responder course at improving participant confidence in first responder abilities and increasing knowledge of trauma response...

Cite
Jackson ME, Ludi EK, Reitz ACW, et al. TRUE-Bolivia (Trauma Responders Unifying to Empower Communities Bolivia) in Santa Cruz, Bolivia. J Surg Res. 2022;273:1-8doi: 10.1016/j.jss.2021.12.006.
Jackson, M. E., Ludi, E. K., Reitz, A. C. W., Moraes Dos Santos, G., Helenowski, I. B., Quiroga, L. L., Foianini, J. E., & Swaroop, M. (2022). TRUE-Bolivia (Trauma Responders Unifying to Empower Communities Bolivia) in Santa Cruz, Bolivia. The Journal of surgical research, 2731-8. https://doi.org/10.1016/j.jss.2021.12.006
Jackson, Morgan E, et al. "TRUE-Bolivia (Trauma Responders Unifying to Empower Communities Bolivia) in Santa Cruz, Bolivia." The Journal of surgical research vol. 273 (2022): 1-8. doi: https://doi.org/10.1016/j.jss.2021.12.006
Jackson ME, Ludi EK, Reitz ACW, Moraes Dos Santos G, Helenowski IB, Quiroga LL, Foianini JE, Swaroop M. TRUE-Bolivia (Trauma Responders Unifying to Empower Communities Bolivia) in Santa Cruz, Bolivia. J Surg Res. 2022 Jan 06;273:1-8. doi: 10.1016/j.jss.2021.12.006. Epub 2022 Jan 06. PMID: 34999516.
Copy Download .nbib Format: NLM
Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities.

Oncotarget

Costa R, Costa RB, Talamantes SM, Helenoswki I, Carneiro BA, Chae YK, Gradishar WJ, Kurzrock R, Giles FJ.
PMID: 28978071
Oncotarget. 2017 Jun 29;8(40):67782-67789. doi: 10.18632/oncotarget.18847. eCollection 2017 Sep 15.

PURPOSE: Anti-PD1 and PD-L1 antibodies are associated with immune-related adverse effects (irAEs). This analysis aims to assess the discrepancies between frequencies of irAEs observed in phase 1 trials with those seen in late-phase trials and to evolve the field...

Cite
Costa R, Costa RB, Talamantes SM, et al. Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities. Oncotarget. 2017;8(40):67782-67789doi: 10.18632/oncotarget.18847.
Costa, R., Costa, R. B., Talamantes, S. M., Helenoswki, I., Carneiro, B. A., Chae, Y. K., Gradishar, W. J., Kurzrock, R., & Giles, F. J. (2017). Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities. Oncotarget, 8(40), 67782-67789. https://doi.org/10.18632/oncotarget.18847
Costa, Ricardo, et al. "Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities." Oncotarget vol. 8,40 (2017): 67782-67789. doi: https://doi.org/10.18632/oncotarget.18847
Costa R, Costa RB, Talamantes SM, Helenoswki I, Carneiro BA, Chae YK, Gradishar WJ, Kurzrock R, Giles FJ. Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities. Oncotarget. 2017 Jun 29;8(40):67782-67789. doi: 10.18632/oncotarget.18847. eCollection 2017 Sep 15. PMID: 28978071; PMCID: PMC5620211.
Copy Download .nbib Format: NLM
Financial burden experienced by patients undergoing treatment for malignant gliomas.

Neuro-oncology practice

Kumthekar P, Stell BV, Jacobs DI, Helenowski IB, Rademaker AW, Grimm SA, Bennett CL, Raizer JJ.
PMID: 26034619
Neurooncol Pract. 2014 Jun;1(2):71-76. doi: 10.1093/nop/npu002. Epub 2014 May 05.

BACKGROUND: Patients undergoing treatment for malignant gliomas (MGs) can encounter medical costs beyond what their insurance covers. The magnitude and type of costs experienced by patients are unknown. The purpose of this study was to have patients or their...

Cite
Kumthekar P, Stell BV, Jacobs DI, et al. Financial burden experienced by patients undergoing treatment for malignant gliomas. Neurooncol Pract. 2014;1(2):71-76doi: 10.1093/nop/npu002.
Kumthekar, P., Stell, B. V., Jacobs, D. I., Helenowski, I. B., Rademaker, A. W., Grimm, S. A., Bennett, C. L., & Raizer, J. J. (2014). Financial burden experienced by patients undergoing treatment for malignant gliomas. Neuro-oncology practice, 1(2), 71-76. https://doi.org/10.1093/nop/npu002
Kumthekar, Priya, et al. "Financial burden experienced by patients undergoing treatment for malignant gliomas." Neuro-oncology practice vol. 1,2 (2014): 71-76. doi: https://doi.org/10.1093/nop/npu002
Kumthekar P, Stell BV, Jacobs DI, Helenowski IB, Rademaker AW, Grimm SA, Bennett CL, Raizer JJ. Financial burden experienced by patients undergoing treatment for malignant gliomas. Neurooncol Pract. 2014 Jun;1(2):71-76. doi: 10.1093/nop/npu002. Epub 2014 May 05. PMID: 26034619; PMCID: PMC4371162.
Copy Download .nbib Format: NLM
Evaluation of a First Responders Course in Rural North India.

The Journal of surgical research

Mohan SC, Bhatia MB, Martinez CR, Suria N, Helenowski I, Thakur N, Bhalla A, Narwal R, Bhoi S, Swaroop M.
PMID: 34438189
J Surg Res. 2021 Aug 23;268:485-490. doi: 10.1016/j.jss.2021.07.023. Epub 2021 Aug 23.

BACKGROUND: Most mortality in trauma occurs in prehospital settings when the golden hour is spent accessing healthcare facilities rather than resuscitating and stabilizing. Assessments performed in the rural community of Nanakpur, India demonstrated a significant paucity of, and limited...

Cite
Mohan SC, Bhatia MB, Martinez CR, et al. Evaluation of a First Responders Course in Rural North India. J Surg Res. 2021;268:485-490doi: 10.1016/j.jss.2021.07.023.
Mohan, S. C., Bhatia, M. B., Martinez, C. R., Suria, N., Helenowski, I., Thakur, N., Bhalla, A., Narwal, R., Bhoi, S., & Swaroop, M. (2021). Evaluation of a First Responders Course in Rural North India. The Journal of surgical research, 268485-490. https://doi.org/10.1016/j.jss.2021.07.023
Mohan, Srivarshini Cherukupalli, et al. "Evaluation of a First Responders Course in Rural North India." The Journal of surgical research vol. 268 (2021): 485-490. doi: https://doi.org/10.1016/j.jss.2021.07.023
Mohan SC, Bhatia MB, Martinez CR, Suria N, Helenowski I, Thakur N, Bhalla A, Narwal R, Bhoi S, Swaroop M. Evaluation of a First Responders Course in Rural North India. J Surg Res. 2021 Aug 23;268:485-490. doi: 10.1016/j.jss.2021.07.023. Epub 2021 Aug 23. PMID: 34438189.
Copy Download .nbib Format: NLM
Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment.

HGG advances

Jiang Y, Meyers TJ, Emeka AA, Cooley LF, Cooper PR, Lancki N, Helenowski I, Kachuri L, Lin DW, Stanford JL, Newcomb LF, Kolb S, Finelli A, Fleshner NE, Komisarenko M, Eastham JA, Ehdaie B, Benfante N, Logothetis CJ, Gregg JR, Perez CA, Garza S, Kim J, Marks LS, Delfin M, Barsa D, Vesprini D, Klotz LH, Loblaw A, Mamedov A, Goldenberg SL, Higano CS, Spillane M, Wu E, Carter HB, Pavlovich CP, Mamawala M, Landis T, Carroll PR, Chan JM, Cooperberg MR, Cowan JE, Morgan TM, Siddiqui J, Martin R, Klein EA, Brittain K, Gotwald P, Barocas DA, Dallmer JR, Gordetsky JB, Steele P, Kundu SD, Stockdale J, Roobol MJ, Venderbos LDF, Sanda MG, Arnold R, Patil D, Evans CP, Dall'Era MA, Vij A, Costello AJ, Chow K, Corcoran NM, Rais-Bahrami S, Phares C, Scherr DS, Flynn T, Karnes RJ, Koch M, Dhondt CR, Nelson JB, McBride D, Cookson MS, Stratton KL, Farriester S, Hemken E, Stadler WM, Pera T, Banionyte D, Bianco FJ, Lopez IH, Loeb S, Taneja SS, Byrne N, Amling CL, Martinez A, Boileau L, Gaylis FD, Petkewicz J, Kirwen N, Helfand BT, Xu J, Scholtens DM, Catalona WJ, Witte JS.
PMID: 34993496
HGG Adv. 2022 Jan 13;3(1). doi: 10.1016/j.xhgg.2021.100070. Epub 2021 Nov 19.

Men diagnosed with low-risk prostate cancer (PC) are increasingly electing active surveillance (AS) as their initial management strategy. While this may reduce the side effects of treatment for prostate cancer, many men on AS eventually convert to active treatment....

Cite
Jiang Y, Meyers TJ, Emeka AA, et al. Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment. HGG Adv. 2021;3(1)doi: 10.1016/j.xhgg.2021.100070.
Jiang, Y., Meyers, T. J., Emeka, A. A., Cooley, L. F., Cooper, P. R., Lancki, N., Helenowski, I., Kachuri, L., Lin, D. W., Stanford, J. L., Newcomb, L. F., Kolb, S., Finelli, A., Fleshner, N. E., Komisarenko, M., Eastham, J. A., Ehdaie, B., Benfante, N., Logothetis, C. J., Gregg, J. R., Perez, C. A., Garza, S., Kim, J., Marks, L. S., Delfin, M., Barsa, D., Vesprini, D., Klotz, L. H., Loblaw, A., Mamedov, A., Goldenberg, S. L., Higano, C. S., Spillane, M., Wu, E., Carter, H. B., Pavlovich, C. P., Mamawala, M., Landis, T., Carroll, P. R., Chan, J. M., Cooperberg, M. R., Cowan, J. E., Morgan, T. M., Siddiqui, J., Martin, R., Klein, E. A., Brittain, K., Gotwald, P., Barocas, D. A., Dallmer, J. R., Gordetsky, J. B., Steele, P., Kundu, S. D., Stockdale, J., Roobol, M. J., Venderbos, L. D. F., Sanda, M. G., Arnold, R., Patil, D., Evans, C. P., Dall'Era, M. A., Vij, A., Costello, A. J., Chow, K., Corcoran, N. M., Rais-Bahrami, S., Phares, C., Scherr, D. S., Flynn, T., Karnes, R. J., Koch, M., Dhondt, C. R., Nelson, J. B., McBride, D., Cookson, M. S., Stratton, K. L., Farriester, S., Hemken, E., Stadler, W. M., Pera, T., Banionyte, D., Bianco, F. J., Lopez, I. H., Loeb, S., Taneja, S. S., Byrne, N., Amling, C. L., Martinez, A., Boileau, L., Gaylis, F. D., Petkewicz, J., Kirwen, N., Helfand, B. T., Xu, J., Scholtens, D. M., Catalona, W. J., & Witte, J. S. (2022). Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment. HGG advances, 3(1), . https://doi.org/10.1016/j.xhgg.2021.100070
Jiang, Yu, et al. "Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment." HGG advances vol. 3,1 (2022). doi: https://doi.org/10.1016/j.xhgg.2021.100070
Jiang Y, Meyers TJ, Emeka AA, Cooley LF, Cooper PR, Lancki N, Helenowski I, Kachuri L, Lin DW, Stanford JL, Newcomb LF, Kolb S, Finelli A, Fleshner NE, Komisarenko M, Eastham JA, Ehdaie B, Benfante N, Logothetis CJ, Gregg JR, Perez CA, Garza S, Kim J, Marks LS, Delfin M, Barsa D, Vesprini D, Klotz LH, Loblaw A, Mamedov A, Goldenberg SL, Higano CS, Spillane M, Wu E, Carter HB, Pavlovich CP, Mamawala M, Landis T, Carroll PR, Chan JM, Cooperberg MR, Cowan JE, Morgan TM, Siddiqui J, Martin R, Klein EA, Brittain K, Gotwald P, Barocas DA, Dallmer JR, Gordetsky JB, Steele P, Kundu SD, Stockdale J, Roobol MJ, Venderbos LDF, Sanda MG, Arnold R, Patil D, Evans CP, Dall'Era MA, Vij A, Costello AJ, Chow K, Corcoran NM, Rais-Bahrami S, Phares C, Scherr DS, Flynn T, Karnes RJ, Koch M, Dhondt CR, Nelson JB, McBride D, Cookson MS, Stratton KL, Farriester S, Hemken E, Stadler WM, Pera T, Banionyte D, Bianco FJ, Lopez IH, Loeb S, Taneja SS, Byrne N, Amling CL, Martinez A, Boileau L, Gaylis FD, Petkewicz J, Kirwen N, Helfand BT, Xu J, Scholtens DM, Catalona WJ, Witte JS. Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment. HGG Adv. 2022 Jan 13;3(1). doi: 10.1016/j.xhgg.2021.100070. Epub 2021 Nov 19. PMID: 34993496; PMCID: PMC8725988.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 34 entries